团队研究:在患有转移性荷尔蒙敏感前列腺癌的患者中进行前期多西治疗:现实世界,多中心,回顾性分析
Chiara Pisano1, Fabio Turco2, Elena Arnaudo2
1Department of Medical Oncology, S Croce e Carle Hospital, Cuneo, Italy.
Clinical genitourinary cancer
|October 5, 2023
概括
预后因素,如格里森评分和基线实验室值,会影响用多塞塔塞尔治疗的转移性激素敏感前列腺癌 (mHSPC) 的结果. 在雄激素剥夺疗法 (ADT) 后早期启动治疗改善了结果.
科学领域:
- 在瘤学瘤学.
- 前列腺癌研究 研究前列腺癌
- 临床试验 临床试验
背景情况:
- 转移性激素敏感前列腺癌 (mHSPC) 的治疗已经发展,三重疗法显示出显著的疗效.
- 确定预后因素对于优化mHSPC治疗选择至关重要.
研究的目的:
- 评估各种临床和实验室变量的预后作用mHSPC患者接受前期dcetaxel.
- 在这个患者队列中确定影响无进展生存 (PFS) 和整体生存 (OS) 的因素.
主要方法:
- 观察性,回顾性研究 (TEAM) 涉及来自意大利11个中心的147名mHSPC患者.
- 患者预先接受了多塞塔克塞尔. 从2014年9月到2020年12月收集的数据.
- 无进展生存率 (PFS) 和总生存率 (OS) 是主要的结果指标.
主要成果:
- 对于PFS的独立预后因素包括格里森评分,阿片类药物使用,基线LDH,以及ADT后的多塞塔克塞尔启动时间.
- 对OS的独立预后因素是基线Hb和LDH.
- 单变量分析确定了许多其他显著变量,包括基线PSA,骨转移和3个月后的PSA反应.
结论:
- 高格利森评分,疾病负担,疼痛,阿片类药物使用和不利的基线实验室预测mHSPC患者在多塞塔克塞尔治疗中的结果会更差.
- 在ADT后更早开始使用多塞塔克塞尔与改善的结果相关.
- 这些预后因素可以为mHSPC中三重治疗候选人的选择提供信息.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K